by jlohrconsulting | Sep 28, 2025 | Uncategorized
J Pharmacol Exp Ther. 2025 Sep 3;392(10):103691. doi: 10.1016/j.jpet.2025.103691. Online ahead of print. ABSTRACT Increasing interest in the therapeutic potential of psychedelics, combined with expanding availability, decreasing perceived risk, and widening efforts...
by jlohrconsulting | Sep 28, 2025 | Uncategorized
Cell J. 2025 Sep 28;27(1):1-12. doi: 10.22074/cellj.2025.2046068.1727. ABSTRACT Depression is among the most widespread mental health conditions worldwide, with a significant number of patients showing inadequate responses to pharmacological treatments. Despite the...
by jlohrconsulting | Sep 28, 2025 | Uncategorized
Inquiry. 2025 Jan-Dec;62:469580251375264. doi: 10.1177/00469580251375264. Epub 2025 Sep 28. ABSTRACT Seafarers’ experiences during the COVID-19 crisis have been associated with increased stress, anxiety and complaints of depression. The consequences of the...
by jlohrconsulting | Sep 28, 2025 | Uncategorized
Behav Brain Res. 2025 Sep 25:115848. doi: 10.1016/j.bbr.2025.115848. Online ahead of print. ABSTRACT BACKGROUND: Parkinson’s disease (PD) is a prevalent neurodegenerative disorder marked by progressive motor and non-motor symptoms. Although levodopa remains the...
by jlohrconsulting | Sep 28, 2025 | Uncategorized
Brain Behav Immun. 2025 Sep 25:106120. doi: 10.1016/j.bbi.2025.106120. Online ahead of print. ABSTRACT INTRODUCTION: Both cardio-metabolic diseases (CMD) and depression carry high burden of disease and have a striking bi-directional comorbidity. Understanding...
by jlohrconsulting | Sep 28, 2025 | Uncategorized
Neurosci Biobehav Rev. 2025 Sep 25:106385. doi: 10.1016/j.neubiorev.2025.106385. Online ahead of print. ABSTRACT Negative symptoms are strongly linked to disability and distress across psychotic and mood disorders. Current treatments are ineffective due to a limited...
Recent Comments